(Reuters) - Drugmaker Biogen Inc (BIIB.O) reported a 7.1% rise in third-quarter profit on Tuesday, boosted by higher demand for its rare muscle disease drug, Spinraza.
Net income attributable to the company rose to $1.55 billion, or $8.39 per share, in the quarter ended Sept. 30, from $1.44 billion, or $7.15 per share, a year earlier. (bit.ly/2N0C8ed)
Total revenue rose to $3.60 billion from $3.44 billion.
Reporting by Manas Mishra and Trisha Roy in Bengaluru; Editing by Arun Koyyur